NO20092279L - Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter - Google Patents

Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter

Info

Publication number
NO20092279L
NO20092279L NO20092279A NO20092279A NO20092279L NO 20092279 L NO20092279 L NO 20092279L NO 20092279 A NO20092279 A NO 20092279A NO 20092279 A NO20092279 A NO 20092279A NO 20092279 L NO20092279 L NO 20092279L
Authority
NO
Norway
Prior art keywords
factor viia
anticoagulants
inhibitors useful
viia inhibitors
macrocyclic
Prior art date
Application number
NO20092279A
Other languages
English (en)
Norwegian (no)
Inventor
Daniel L Cheney
Nicholas R Wurtz
Peter W Glunz
Xiaojun Zhang
Eldon Scott Priestley
Vladimir Ladziata
Brandon Parkhurst
Luciano Mueller
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20092279L publication Critical patent/NO20092279L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20092279A 2006-12-20 2009-06-12 Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter NO20092279L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87086406P 2006-12-20 2006-12-20
US98446007P 2007-11-01 2007-11-01
PCT/US2007/088032 WO2008079836A2 (en) 2006-12-20 2007-12-19 Macrocyclic factor viia inhibitors useful as anticoagulants

Publications (1)

Publication Number Publication Date
NO20092279L true NO20092279L (no) 2009-08-31

Family

ID=39430763

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092279A NO20092279L (no) 2006-12-20 2009-06-12 Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter

Country Status (12)

Country Link
US (1) US8420830B2 (enExample)
EP (1) EP2102176A2 (enExample)
JP (1) JP2010514681A (enExample)
AR (1) AR064471A1 (enExample)
AU (1) AU2007337025A1 (enExample)
CA (1) CA2673598A1 (enExample)
CL (1) CL2007003718A1 (enExample)
MX (1) MX2009006689A (enExample)
NO (1) NO20092279L (enExample)
PE (1) PE20081775A1 (enExample)
TW (1) TW200836735A (enExample)
WO (1) WO2008079836A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010513562A (ja) 2006-12-20 2010-04-30 ブリストル−マイヤーズ スクイブ カンパニー 抗凝血剤として有用な二環状ラクタム第ｖｉｉａ因子阻害剤
IN2012DN05081A (enExample) * 2009-12-08 2015-10-09 Boehringer Ingelheim Int
JP5844287B2 (ja) 2010-02-11 2016-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としてのマクロ環
CN102993065B (zh) * 2011-09-13 2015-07-29 中国科学院上海药物研究所 含手性叔丁基亚磺酰基的α-芳基氨基酸酯类化合物、其制备方法及用途
LT2766346T (lt) 2011-10-14 2017-06-12 Bristol-Myers Squibb Company Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai
RU2632659C2 (ru) * 2011-12-27 2017-10-09 Байо-Фарм Солюшнс Ко., Лтд. Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
WO2013184734A1 (en) 2012-06-08 2013-12-12 Bristol-Myers Squibb Company Macrocyclic factor viia inhibitors
CA2880898A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
KR20150038372A (ko) 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
HRP20180465T1 (hr) 2012-10-12 2018-05-04 Bristol-Myers Squibb Company Kristalni oblici inhibitora faktora xia
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
EP3008052A1 (en) * 2013-06-13 2016-04-20 Bristol-Myers Squibb Company Macrocyclic factor viia inhibitors
NO2760821T3 (enExample) 2014-01-31 2018-03-10
JP6505727B2 (ja) 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3072943B1 (en) 2015-03-26 2018-05-02 Idemitsu Kosan Co., Ltd. Dibenzofuran/carbazole-substituted benzonitriles
ES2871111T3 (es) * 2015-07-29 2021-10-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
US5023236A (en) 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5843442A (en) 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5866542A (en) 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1332131A2 (en) * 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002322802A1 (en) * 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US7122559B2 (en) * 2003-02-11 2006-10-17 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
US7144895B2 (en) * 2003-02-11 2006-12-05 Bristol-Myers Squibb Co. Benzene acetamide compounds useful as serine protease inhibitors
AR054321A1 (es) * 2005-01-10 2007-06-20 Bristol Myers Squibb Co Derivados en fenilglicinamida utiles como anticoagulantes
JP2008538102A (ja) * 2005-03-03 2008-10-09 ザ バーナム インスティテュート フォー メディカル リサーチ バーチャルドッキングアプローチを適用したプロテインキナーゼｂ阻害剤のスクリーニング方法並びにそれにより見出された化合物及び組成物
DE602006011752D1 (de) * 2005-06-24 2010-03-04 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
TW200745062A (en) * 2005-12-23 2007-12-16 Bristol Myers Squibb Co Macrocyclic factor VIIA inhibitors useful as anticoagulants
US8044242B2 (en) 2006-03-09 2011-10-25 Bristol-Myers Squibb Company 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants
JP2010513562A (ja) 2006-12-20 2010-04-30 ブリストル−マイヤーズ スクイブ カンパニー 抗凝血剤として有用な二環状ラクタム第ｖｉｉａ因子阻害剤

Also Published As

Publication number Publication date
PE20081775A1 (es) 2008-12-18
US8420830B2 (en) 2013-04-16
JP2010514681A (ja) 2010-05-06
TW200836735A (en) 2008-09-16
AU2007337025A1 (en) 2008-07-03
WO2008079836A2 (en) 2008-07-03
CA2673598A1 (en) 2008-07-03
EP2102176A2 (en) 2009-09-23
WO2008079836A3 (en) 2009-01-15
CL2007003718A1 (es) 2008-07-11
MX2009006689A (es) 2009-06-30
AR064471A1 (es) 2009-04-01
WO2008079836A4 (en) 2009-03-12
US20100113488A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
WO2008079836A3 (en) Macrocyclic factor viia inhibitors useful as anticoagulants
NO20082629L (no) Macrocyklisk factor VIIa-inhibitorer anvendbare som antikoagulanter
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
NO20092050L (no) Nye sulfonamidderivater som bradykininantagonister
NO20083434L (no) Benzamid- og heteroarenderivater
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
TNSN08407A1 (en) Organic compounds
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
MX2009012418A (es) Derivados de quinazolin-oxima como inhibidores de hsp90.
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
NO20054852L (no) GFAT inhibitorer
NO20081217L (no) Nye benzotiazolonderivater
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20080717L (no) Oksimderivat og fremgangsmate for fremstilling av dette
TW200833675A (en) Nicotinamide derivatives
MY129796A (en) Novel anti-inflammatory androstane derivatives
WO2009001060A3 (en) Use of compounds for preparing anti-tuberculosis agents
NO20064077L (no) Kemokinreseptorantagonister
NO20092048L (no) Nye benzamidderivater som bradykininantagonister
MX2008012332A (es) Tiazolil-dihidro-indazoles.
NO20085107L (no) Spirosykliske nitriler som proteaseinhibitorer
NO20092058L (no) Heteroaryl pyrrolidinyl ketonderivater
TW200745032A (en) Novel heterobicyclic derivatives
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20092226L (no) Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application